Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BSI 001

Next Previous
X
Search
Drug Profile

BSI 001

Alternative Names: Anti-HER2 monoclonal antibody - Biosion; BSI-001

Latest Information Update: 22 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosion
  • Developer Anhui Anke Biotechnology; Biosion
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Gastric cancer

Highest Development Phases

  • Preclinical Breast cancer; Gastric cancer; Solid tumours

Most Recent Events

  • 12 Sep 2022 Preclinical trials in Solid tumours in China (Parenteral) (Biosion pipeline, September 2022)
  • 12 Sep 2022 Anhui Anke Biotechnology plans to files an IND application with the NMPA in China for Solid tumours in second half of 2023 (Biosion pipeline, September 2022)
  • 31 Jul 2022 BSI 001 licensed to Anhui Anke Biotechnology for development and commericalisation in China(Biosion pipeline, September 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top